Partner Therapeutics Inc, a US-based integrated biotechnology company, announced on Monday that it has collaborated with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, and Labcorp Drug Development, a United States-based contract research organisation, to advance a new diagnostic approach to certain immunoparalysed sepsis patients that could benefit most from Leukine (sargramostim).

Partner Therapeutics will be able to identify sepsis patients demonstrating an immune suppressed, or immunoparalysed state and clinically evaluate Leukine as a study therapy in these individuals based on the advancement of a Laboratory Developed Test for monocyte HLA-DR.

The collaboration will use Partner Therapeutics' previous experience developing Leukine for Acute Radiation Syndrome, an FDA approved indication, and present clinical research for use of Leukine in patients with diverse immunosuppressed conditions.